EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor

Hiroaki Echigo, Masayuki Munekane, Takeshi Fuchigami, Kohshin Washiyama, Kenji Mishiro, Hiroshi Wakabayashi, Kazuhiro Takahashi, Seigo Kinuya, Kazuma Ogawa iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06695-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Hiroaki Echigo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Ishikawa, Japan. Hauptthemen laut MEDLINE: Oligopeptides. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Mitani Foundation for Research and Development, Terumo Foundation for Life Sciences and Arts.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

A probe for targeted alpha therapy (TAT) using the RGD peptide (Ga-DOTA-K([ 211 At]APBA)-c(RGDfK) ([ 211 At] 1 )) with albumin-binding moiety (ABM) was recently developed. [ 211 At] 1 highly accumulated in tumors and significantly inhibited tumor growth in U-87 MG tumor-bearing mice. However, high [ 211 At] 1 retention in blood may cause critical adverse events, such as hematotoxicity. Therefore, we attempted to accelerate the blood clearance of [ 211 At] 1 by competitively inhibiting the binding of [ 211 At] 1 to albumin to modulate the pharmacokinetics of the former.

Methods

To evaluate the effects of albumin-binding inhibitors in normal mice, sodium 4-(4-iodophenyl)butanoate at 2, 5, or 10 molar equivalents of blood albumin was administered at 1-h postinjection of [ 211 At] 1 . The biodistribution of [ 211 At] 1 , SPECT/CT imaging of [ 67 Ga]Ga-DOTA-K(IPBA)-c(RGDfK) ([ 67 Ga] 2 ), and the therapeutic effects of [ 211 At] 1 were compared with or without IPBA administration in U-87 MG tumor-bearing mice.

Results

Blood radioactivity of [ 211 At] 1 was decreased in a dose-dependent manner with IPBA in normal mice. In U-87 MG tumor-bearing mice, the blood radioactivity and accumulation in nontarget tissues of [ 211 At] 1 were decreased by IPBA. Meanwhile, tumor [ 211 At] 1 accumulation was not changed at 3-h postinjection of IPBA. In SPECT/CT imaging of [ 67 Ga] 2 , IPBA administration dramatically decreased radioactivity in nontarget tissues, and only tumor tissue was visualized. In therapeutic experiments, [ 211 At] 1 with IPBA injected-group significantly inhibited tumor growth compared to the control group.

Conclusion

IPBA administration (as an albumin-binding inhibitor) could modulate the pharmacokinetics and enhance the therapeutic effects of [ 211 At] 1 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligopeptidesAnimalsMiceTissue DistributionCell Line, TumorHumansRadiopharmaceuticalsAlbuminsProtein BindingMaleIsotope LabelingSerum AlbuminFemaleSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

Albumin-binding moiety (ABM)Astatine-211RGD peptideRadiotheranosticsTargeted alpha therapy (TAT)

Substanzen

Oligopeptidesarginyl-glycyl-aspartic acidRadiopharmaceuticalsAlbuminsSerum Albumin

Autor:innen und Institutionen

  • Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Ishikawa, Japan.
  • Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
  • Institute for Frontier Science Initiative, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Ishikawa, Japan.
  • Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-Machi 13-1, Kanazawa, 920-8641, Ishikawa, Japan.
  • Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Ishikawa, Japan. kogawa@p.kanazawa-u.ac.jp.
  • Institute for Frontier Science Initiative, Kanazawa University, Kakuma-Machi, Kanazawa, 920-1192, Ishikawa, Japan. kogawa@p.kanazawa-u.ac.jp.

ORCID-Profile: Kazuma Ogawa

Förderung

  • Japan Society for the Promotion of Science
  • Mitani Foundation for Research and Development
  • Terumo Foundation for Life Sciences and Arts
  • Kanazawa University

Zitieren

APA

Echigo, H., Munekane, M., Fuchigami, T., Washiyama, K., Mishiro, K., Wakabayashi, H., Takahashi, K., Kinuya, S., & Ogawa, K. (2024). Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06695-w

Vancouver

Echigo H, Munekane M, Fuchigami T, Washiyama K, Mishiro K, Wakabayashi H, et al. Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06695-w

BibTeX
@article{Echigo2024,
  author = {Echigo, Hiroaki and Munekane, Masayuki and Fuchigami, Takeshi and Washiyama, Kohshin and Mishiro, Kenji and Wakabayashi, Hiroshi and Takahashi, Kazuhiro and Kinuya, Seigo and Ogawa, Kazuma},
  title = {Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06695-w}
}
Kostenlos starten →